Probucol: Pharmacology and Clinical Application
- 1 January 1990
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 30 (1) , 3-9
- https://doi.org/10.1002/j.1552-4604.1990.tb03431.x
Abstract
Increased levels of cholesterol, LDL‐cholesterol, and VLDL‐cholesterol are known risk factors for the development of atherosclerotic vascular disease. Probucol is an orally active agent that can reduce total cholesterol and LDL‐cholesterol. The drug also reduces HDL‐cholesterol. However, it may modify the lipoprotein in such a way that removal of cholesterol from peripheral tissues is still enhanced. Probucol also has antioxidant activity, which may inhibit the oxidative modification of LDL that contributes to lipid deposition in blood vessel walls. Probucol is a well tolerated agent. However, its ability to prolong life in human subjects still needs to be determined.Keywords
This publication has 25 references indexed in Scilit:
- Probucol, high-density lipoprotein metabolism and reverse cholesterol transportThe American Journal of Cardiology, 1988
- Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol quantitative regression Swedish trial (PQRST): A status reportThe American Journal of Cardiology, 1988
- Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesionsThe American Journal of Cardiology, 1988
- Effect of probucol on development of diabetes mellitus in BB ratsThe American Journal of Cardiology, 1988
- Lipoprotein oxidation and cytotoxicity: Effect of probucol on streptozotocin-treated ratsThe American Journal of Cardiology, 1988
- In vivo inhibition of foam cell development by probucol in Watanabe rabbitsThe American Journal of Cardiology, 1988
- Probucol in long-term treatment of hypercholesterolemiaGeneral Pharmacology: The Vascular System, 1988
- Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery diseaseThe American Journal of Cardiology, 1986
- Controlled studies of the efficacy and safety of combined probucol-colestipol therapyThe American Journal of Cardiology, 1986
- LOWERED HDL CHOLESTEROL AND INCIDENCE OF ISCHAEMIC HEART DISEASEThe Lancet, 1981